Vaccinogen Inc.
Funding rounds
3 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Oct 2012 | $7 M | No. 3 | $2 to $10 million | equity | SEC | |
| Feb 2010 | $8 M | No. 2 | $2 to $10 million | equity | SEC | |
| Dec 2008 | $4 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Vaccinogen Inc. chose not to state its revenue in its newest notice of a funding round (Jan 2014).
SEC Form D · Jan 2014
The industry group it chose in its notices: Biotechnology.
SEC Form D · Jan 2014
That is all the official record says: Vaccinogen Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
In its own words
How the company describes itself to search engines on its website, word for word.
“Welcome to Vaccinogen Inc, your personal guide to the top game developers and software providers, history facts, and today's connection with online casinos.”
Source: The company's website · as of Nov 15, 2026
Products and services#
No products or services on record: its website does not describe any in structured form (a page that declares itself a product or service), and Wikidata lists none.
Investors#
No investor of Vaccinogen Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 68 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Andrew L. Tussing | Executive officer | Jan 2014 |
| Michael G. Hanna, Jr. | Executive officer | Jan 2014 |
| Michael L. Kranda | Executive officer | Jun 2011 |
| Alan L. Cohen | Director | Jan 2014 |
| Daniel L. Fitzgerald | Director | Jan 2014 |
| Daniel L. Kane | Director | Jan 2014 |
| John L. Nicolis | Director | Jan 2014 |
| Michael G. Hanna, Jr. | Director | Jan 2014 |
| Michael L. Kranda | Director | Jun 2011 |
| David L. Hatt | Board of Directors Member | Mar 2010 |
| Gregory H. Barnhill | Board of Directors Member | Mar 2010 |
| Tony L. Caplin | Board of Directors Member | Mar 2010 |
About
American biotechnology company.